

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 February 2006 (23.02.2006)

PCT

(10) International Publication Number  
**WO 2006/017929 A1**

- (51) International Patent Classification<sup>7</sup>: C12N 15/70, C12P 21/00, C07K 19/00
- (21) International Application Number: PCT/CA2005/001249
- (22) International Filing Date: 12 August 2005 (12.08.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/522,125 18 August 2004 (18.08.2004) US
- (71) Applicant (for all designated States except US): **GOVERNORS OF THE UNIVERSITY OF ALBERTA** [CA/CA]; 4000 Research Transition Facility, 8308 - 114 Street, Edmonton, Alberta T6G 2E1 (CA).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **WEINER, Joel** [CA/CA]; 41 Fairway Drive, Edmonton, Alberta T6J 2C2 (CA). **ZHANG, Guijin** [CA/CA]; 4112 Tompkins Way, Edmonton, Alberta T6R 3B4 (CA).
- (74) Agent: **BENNETT JONES LLP**; Attention: Susan L. Rancourt, 4500 Bankers Hall East, 855 2nd Street SW, Calgary, Alberta T2P 4K7 (CA).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROTEIN PRODUCTION METHOD UTILIZING YEBF

(57) Abstract: A method of producing a protein or polypeptide, in which an expression vector that encodes a fusion protein comprising the protein or polypeptide peptide located carboxy-terminally to YebF, or a biologically active variant or portion thereof, is expressed in a suitable bacterial cell, to make the fusion protein. The method may further comprise the step of purifying the secreted fusion protein from the growth medium. The fusion protein may further comprise a peptide tag, or a protein cleavage site to separate the protein or polypeptide from the YebF portion, or the tag. Expression of a fusion protein into the culture medium provides a starting material for purification, in which the secreted fusion protein is relatively pure.



WO 2006/017929 A1

## PROTEIN PRODUCTION METHOD UTILIZING YEBF

This application claims priority to US provisional application no. 60/522,125, the entirety of which is incorporated herein by reference.

### FIELD

The present invention relates to the field of secretion of proteins by host cells, into a growth medium.

### BACKGROUND

Protein secretion from bacteria plays an important role in many aspects of the bacterial life cycle, including the formation of pili and flagella, the secretion of extracellular enzymes to digest polymers for nutritional purposes and the secretion of toxins to kill host cells in infections of humans, animals and plants. It is generally accepted that non-pathogenic laboratory strains of *E. coli*, particularly K12 strains, do not naturally secrete proteins into the extracellular medium under routine growth conditions<sup>6,8</sup>, although gene sequence analysis implies the possible existence of a protein secretion pathway<sup>6</sup>. Pugsley has postulated that this system has been lost as a result of prolonged laboratory passage and storage over many decades<sup>6</sup>.

*Bacillus subtilis* has a well characterized protein excretion system for extracellular enzymes such as  $\alpha$ -amylase and subtilin and this organism has been used as an alternative for the extracellular production of recombinant proteins<sup>7</sup>. Compared to *E. coli*, however, *B. subtilis* has several disadvantages including plasmid instability, lack of suitable expression control systems and degradation of the recombinant proteins in the culture medium by the high level of proteolytic enzymes that are also secreted from these cells<sup>7</sup>. In addition, compared with *E. coli*, a relatively long culture period is required for *B. subtilis*.

Other investigators have examined the secretion of proteins in *E. coli*. He *et al.*<sup>10</sup> introduced a cluster of *out* genes (~12kb) carried on a cosmid to *E. coli* cells whose chromosome had *Erwinia* pectate lyase gene integrated. The *out* genes encode the

secretion apparatus of *Erwinia chrysanthemi*, an enterobacterial plant pathogen. With the help of *out* gene expression, *E. coli* could secrete the enzyme to the medium. Pugsley's group<sup>8</sup> has shown that *E. coli* cells can secrete *Klebsiella oxytoca* pullulanase into the medium by co-expressing 14 *Klebsiella* secretion machinery genes cloned on a second plasmid. Pugsley's group<sup>11</sup> has also shown that the secretion of an endogenous *E. coli* chitinase into the medium can occur by co-expressing a cluster of *E. coli gsp* genes carried on a second plasmid in PAP5066, an *hns*-inactivated *E. coli* K12 strain. The *gsp* genes encode the putative type II secretion machinery proteins of *E. coli* and are silenced by H-NS protein, a global regulator and nucleoid-structuring protein<sup>11</sup>. Overall, these excretion studies required the artificial induction of secretion machinery proteins.

In *E. coli* K12, there are 2 well-identified protein transport pathways across the cytoplasmic membrane– the *sec*-dependent pathway or the general secretion pathway (GSP) and the *sec*-independent Mtt/Tat pathway<sup>12</sup>. The GSP of gram-negative bacteria, has at least six different terminal branches depending on the secretion pathway in the outer membrane<sup>13</sup>. Genomic analysis of *E. coli* has identified genes that are homologous to genes encoding secretion proteins in other bacteria. These include *gsp* and *yacC* (*gspS*) homologous to *Klebsiella pulS*<sup>11</sup>, found at 74.5 and 2.95 minutes on the *E. coli* chromosome, respectively. Although these genes appear to encode functional proteins<sup>14</sup>, their transcription is turned off under standard growth condition<sup>6</sup>. *gsp* genes, for example, are silenced by H-NS as mentioned above<sup>11</sup>.

*E. coli* is the most widely used bacterium for protein expression both in research and in industry. As it is desirable to have a secretion system in common laboratory strains, investigators have explored different ways of producing recombinant proteins in the medium<sup>5</sup>. The accumulation of recombinant proteins in the culture medium has the potential to offer a number of benefits including, increased protein production and purity, reduction in cellular toxicity of over-expressed proteins, avoidance of the formation of inclusion bodies and protein degradation by cytoplasmic proteolytic enzymes. It has also been found that proper recombinant protein folding is enhanced by the more favorable redox potential in the medium<sup>5</sup>.

Based on sequence motif algorithms, the *E. coli yebF* gene is predicted to encode a small lipoprotein (Blattner B1847 or Swiss-Prot P33219) of unknown function attached to the

membrane. The *yebF* gene is part of the *yebGFE* operon that is negatively regulated by LexA<sup>1,9</sup>. *yebF* gene expression has been observed under several stress conditions including UV irradiation<sup>2</sup> and DNA damage induced by mitomycin C<sup>3,9</sup>. However, little else has been reported.

## SUMMARY

YebF is a small (10.8 kD) soluble endogenous protein that is naturally secreted into the culture medium by *E. coli* cells. Commonly used laboratory strains HB101 (a hybrid of *E. coli* K12 and B strains), BL21(DE3) (a B strain) and MG1655 (a K12 strain) secrete YebF into the medium under standard laboratory conditions.

YebF can be used to transport proteins into the growth medium. Fusion proteins comprising YebF and human interleukin-2 (hIL2), the short form of *B. subtilis* X23  $\alpha$ -amylase gene<sup>8</sup> lacking the signal sequence and leaderless *E. coli* alkaline phosphatase, have been expressed and secreted in *E. coli*. Therefore, YebF can be used to direct the secretion of proteins, polypeptides and peptides into the medium. Further, the secreted fusion proteins are active.

hIL2 is a 15kD hydrophobic protein<sup>15</sup>, the short form of  $\alpha$ -amylase is a 48 kD hydrophilic protein, and leaderless *E. coli* alkaline phosphatase is a hydrophilic protein. Therefore, YebF can direct the secretion of both hydrophobic and hydrophilic proteins to the medium. Further, YebF can carry proteins of varying size to the medium. However, it was noted that the secreted YebF-hIL2 fusion was sensitive to proteolytic degradation in the medium.

When the fusion protein is further engineered to comprise a peptide tag, such as a His6 tag, the secreted fusion protein can be readily purified from the medium, for example by affinity chromatography, or it can be readily identified, for example with a fluorescent antibody. Expression of a fusion protein into the culture medium provides a starting material for purification wherein the secreted fusion protein is relatively pure, as compared to proteins expressed in the cytoplasm. Therefore subsequent purification steps may be simpler and less expensive. Further, production of secreted fusion proteins in the medium could reduce the contamination of these proteins with lipopolysaccharides in the purified product<sup>16</sup>.

Therefore, in one aspect this invention is a method of producing a protein, polypeptide or peptide of interest that comprises:

- (a) providing an expression vector that encodes a fusion protein comprising the protein, polypeptide or peptide of interest located carboxy-terminally to YebF, or a biologically active variant or portion thereof, and
- (b) expressing the fusion protein in a suitable bacterial cell to thereby generate a secreted fusion protein.

The bacterial cell can be *Escherichia coli*. The method may further comprise the step of purifying a secreted fusion protein from the medium in which the bacterial cell is growing. The fusion protein may further comprise at least one tag or at least one protein cleavage site.

In another aspect the invention is a method of secreting a protein, polypeptide or peptide of interest from a bacterial cell into the growth medium comprising:

- (a) making an expression vector that comprises a recombinant DNA molecule that further comprises a nucleotide sequence that encodes the protein, polypeptide or peptide of interest joined in frame to a nucleotide sequence that encodes YebF, or a biologically active variant or portion thereof,
- (b) transfecting the expression vector into the bacterial cell, and
- (c) expressing the protein encoded by the recombinant DNA molecule in the bacterial cell under conditions that direct the secretion of the protein into the growth medium.

The bacterial cell may be *Escherichia coli*. The recombinant DNA molecule may further comprise at least one nucleotide sequence that encodes a tag or a protein cleavage site.

In another aspect, the invention is the use of YebF, or a biologically active variant or portion thereof to direct the secretion of a protein, polypeptide or peptide of interest into bacterial growth medium.

The YebF, or a biologically active variant or portion thereof may be part of a fusion protein that further comprises the protein, polypeptide or peptide of interest. The YebF, or a biologically active variant or portion thereof may be fused amino-terminally to the protein, polypeptide or peptide of interest.

In yet another aspect, the invention is an expression vector that encodes YebF, or a biologically active variant or portion thereof operatively linked to control nucleotide sequences that direct the transcription and the synthesis of the YebF or a biologically active variant or portion thereof.

In yet another aspect, the invention is an expression vector that encodes a fusion protein comprising YebF, or a biologically active variant or portion thereof and a protein, polypeptide or peptide of interest. The nucleotide sequence that encodes the protein, polypeptide or peptide of interest may be located downstream of the nucleotide sequence that encodes YebF, or a biologically active variant or portion thereof. The expression vector may be for use in *Escherichia coli*. The expression vector may further encode a fusion protein that further comprises at least one tag.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1.** Alignment of the leader sequences of *E. coli* YebF protein and homologues from other bacteria. *E. coli* (SEQ ID NO: 14); *S. flexneri* (SEQ ID NO: 15); *S. typhi* (SEQ ID NO: 16); *Y. pestis* (SEQ ID NO: 17); *P. luminescens* (SEQ ID NO: 18).

**Figure 2.** Western blot demonstrating the subcellular localization of *E. coli* YebF and mature YebF. Symbols: S, spheroplasts; P, periplasm; H, hypertonic solution; M, medium (Panel A). Western blot demonstrating secretion of mature YebF protein from *E. coli* cells over time. Lanes 1-7 show the cells (0 – 180 min) and lanes 8-14 show the medium (0 – 180 min) at 30 min time intervals. Lane F is purified YebF-His<sub>6</sub> (Panel B)

**Figure 3.** Protein profiles in the medium from HB101 cells harbouring pMS119EH (Ctr lanes) or pYebFH<sub>6</sub>/MS (YebF lanes). Samples were collected at the times indicated after induction with 0.1 mM IPTG. Proteins were separated on a 10% SDS-Tricine gel.

**Figure 4.** Maldi-TOF linear mode mass spectrometry of purified *E. coli* YebF protein with a 6-histidine tag.

**Figure 5.** Western blot demonstrating localization of YebF and mature YebF and CRP in cells (C) or medium (M), over time. YebF and mature YebF were detected with anti-His antibody (Panel A), CRP was detected with anti-CRP antibody (Panel B). Lane F in panel A is the purified YebF-His<sub>6</sub>.

**Figure 6.** Panel A:  $\alpha$ -amylase activity of the various fluids and subcellular fractions of HB101 cells harboring: (a) a short form  $\alpha$ -amylase gene fused to *yebF* gene (pYebF-AmyH<sub>6</sub>), (b) a short form  $\alpha$ -amylase gene fused to the *sec*-leader sequence of *yebF* (pLS-AmyH<sub>6</sub>), and (c) a short form  $\alpha$ -amylase gene (pAmyH<sub>6</sub>). Data is the average of three replicates with the standard deviation shown.

Panel B: Protein profiles in the medium. HB101 cells harbouring pAmyH<sub>6</sub> (A lanes), pLS-AmyH<sub>6</sub> (B lanes) and pYebF-AmyH<sub>6</sub> (C lanes) were grown in TB. Protein samples from the medium harvested at the indicated time after induction were prepared as in Methods and Materials. Proteins were separated on 10% SDS-PAGE.

**Figure 7.** Distribution of YebF- $\alpha$ -amylase and alkaline phosphatase, a periplasmic enzyme. Activities shown are the average of two determinations (Panel A). MIC (Minimum Inhibitory Concentrations) test of HB101 cells harboring the plasmids for the antibiotics indicated in the Table. (Panel B) pBR322-tet and pYebFH<sub>6</sub>/MS-tet are tetracycline resistant. The remainder are amp-resistant.

**Figure 8.** Western blotting demonstrating secretion of mature YebF from *E. coli* HB101/pYebFH<sub>6</sub>/MS (HB), BL21(DE3)/pYebFH<sub>6</sub>/T7 (BL) and MG1655/pYebFH<sub>6</sub>/MS (MG) cells. Lane F, purified YebF-His<sub>6</sub>.

**Figure 9.** Western blotting demonstrating the secretion of mature YebF-hIL2 fusion protein from HB101 harboring pYebF-hIL2H<sub>6</sub>/MS. Panel A: shows the localization of YebF-hIL2 by immunoblotting using an anti-6xhistidine tag antibody. Lane M1, medium + 10mM DTT; C1, cells + 10mM DTT; M2, medium – DTT; C2, cells – DTT.

Panel B shows the activities of the secreted mature YebF-hIL2 fusion protein in the diluted medium. The bar labeled “600 units/ml” corresponds to standard hIL-2 with the well containing 50  $\mu$ l of 600 units of hIL-2/ml in RHF<sub>6</sub>M medium (see Materials and Methods) and 50  $\mu$ l of CTLL-2 cells. The bar labeled “negative” is a negative control in

which RHFM without hIL-2 was used. The bar labeled "medium" corresponds to ten times diluted medium from HB101/pMS119EH. The *E. coli* culture medium harvested 3 hours after induction was filtered through a 0.22  $\mu$ m Millipore filter and then diluted with RHFM at the ratios indicated. Each bar was averaged from triplicate wells.

**Figure 10.** Secretion of mature YebF- $\alpha$ -amylase fusion protein over time from HB101 harboring pYebF-AmyH<sub>6</sub>. Samples were taken at 2 hour intervals following 0.1 mM IPTG induction and assayed for  $\alpha$ -amylase activity. Growth was monitored with a Klett spectrophotometer equipped with a red filter.  $\alpha$ -amylase activity in the cells and the medium was expressed in units per ml of the original culture.

**Figure 11.** The sequence of pYebFH6/MS (SEQ ID NO: 19). The ribosome binding site is in bold, and the YebF coding region with a 6-histidine tag is underlined.

**Figure 12.** The physical map of pYebFH6/MS.

## DETAILED DESCRIPTION

Disclosed herein is a method for secreting a protein, polypeptide or peptide of interest into bacterial growth medium. Also disclosed herein is a method of producing a protein, polypeptide or peptide of interest. The method utilizes YebF, or a biologically active variant or portion thereof, to direct or cause the protein, polypeptide or peptide of interest, to be secreted as a fusion protein into the bacterial growth medium. The fusion protein comprises YebF, or a biologically active variant or portion thereof fused to a protein, polypeptide or peptide of interest. The fusion protein may optionally be tagged and may optionally comprise an amino acid sequence that permits cleavage of the YebF encoded portion and/or the tag, from the protein, polypeptide or peptide of interest.

To facilitate understanding of the invention, a number of terms are defined below.

The term "nucleotide" refers to a ribonucleotide or a deoxyribonucleotide. "Nucleic acid" refers to a polymer of nucleotides and may be single- or double-stranded. "Polynucleotide" refers to a nucleic acid that is twelve (12) or more nucleotides in length.

The term "nucleotide sequence of interest" refers to any nucleotide sequence that encodes a "protein, polypeptide or peptide sequence of interest", the production of which may be



deemed desirable for any reason, by one of ordinary skill in the art. Such nucleotide sequences include, but are not limited to, coding sequences of structural genes (*e.g.*, reporter genes, selection marker genes, oncogenes, drug resistance genes, growth factor genes, etc.), regulatory genes (*e.g.*, genes encoding activator protein 1 (AP1), activator protein 2 (AP2), Sp1, etc.), antibody genes, enzyme genes, etc., or portions thereof. The nucleotide sequence of interest may comprise the coding sequence of a gene from one of many different organisms (*e.g.*, mammalian, insect, bacterial, and viral genes).

A nucleotide sequence "encodes" or "codes for" a protein if the nucleotide sequence can be translated to the amino acid sequence of the protein. The nucleotide sequence does not have to contain an actual translation start codon or termination codon.

A "protein, polypeptide or peptide sequence of interest" is encoded by the "nucleotide sequence of interest". The protein, polypeptide or peptide may be a protein from any organism, including but not limited to, mammals, insects, micro-organisms such as bacteria and viruses. It may be any type of protein, including but not limited to, a structural protein, a regulatory protein, an antibody, an enzyme, an inhibitor, a transporter, a hormone, a hydrophilic or hydrophobic protein, a monomer or dimer, a therapeutically-relevant protein, an industrially-relevant protein, or portions thereof.

"Expression" as used herein refers to transcription or translation, or both, as context requires.

"Secretion" as used herein refers to the excretion of the fusion protein that is expressed in a bacterium, into the bacterial growth medium.

"YebF" is a reference to the protein having the following amino acid sequence (SEQ ID NO: 1)

```
MKKRGA FLGLLLVSAC ASVFAANNET SKSVTFPKCE DLDAAGIAAS  
VKRDYQQNRV ARWADDQKIV GQADPVAWVS LQDIQ GKDDK WSVPLTVRGK  
SADIHYQVSV DCKAGMAEYQ RR
```

"Mature YebF" is a reference to the protein having the following amino acid sequence (SEQ ID NO: 2)

ANNET SKSVTFPKCE DLDAAGIAAS VKRDYQQNRV ARWADDQKIV GQADPVAWVS  
LQDIQKGDDK WSVPLTVRGK SADIHYQVSV DCKAGMAEYQ RR

*yebF* is a reference to a nucleic acid or a nucleotide sequence having the following sequence (SEQ ID NO: 3):

```
atg aaa aaa aga ggg gcg
ttt tta ggg ctg ttg ttg gtt tct gcc tgc
gca tca gtt ttc gct gcc aat aat gaa acc
agc aag tcg gtc act ttc cca aag tgt gaa
gat ctg gat gct gcc gga att gcc gcg agc
gta aaa cgt gat tat caa caa aat cgc gtg
gcg cgt tgg gca gat gat caa aaa att gtc
ggt cag gcc gat ccc gtg gct tgg gtc agt
ttg cag gac att cag ggt aaa gat gat aaa
tgg tca gta ccg cta acc gtg cgt ggt aaa
agt gcc gat att cat tac cag gtc agc gtg
gac tgc aaa gcg gga atg gcg gaa tat cag
cgg cgt taa
```

The terms “modified”, “mutant” or “variant” are used interchangeably herein, and refer to: (a) a nucleotide sequence in which one or more nucleotides have been added or deleted, or substituted with different nucleotides or modified bases (*e.g.*, inosine, methylcytosine) or to (b) a protein, peptide or polypeptide in which one or more amino acids have been added or deleted, or substituted with a different amino acid. A variant may be naturally occurring, or may be created experimentally by one of skill in the art. A variant of YebF or *yebF* may be a protein, peptide, polypeptide or polynucleotide that differs (*i.e.*, an addition, deletion or substitution) in one or more amino acids or nucleotides from the sequence of YebF or *yebF*, respectively.

In this regard, it is well understood in the art that certain alterations inclusive of mutations, additions, deletions and substitutions can be made to a reference nucleic acid or protein, whereby the altered nucleic acid or protein retains a particular biological function or activity, or perhaps displays an altered but nevertheless useful activity. Some deletions, insertions and substitutions will not produce radical changes in the characteristics in the YebF protein or in the *YebF* nucleic acid. However, while it may be difficult to predict the exact effect of the substitution, deletion or insertion in advance of doing so, one skilled in the art will appreciate that the effect can be evaluated by routine screening assays. For example whether a variant of YebF has a secretory function can be determined by assaying for whether the YebF variant, or a fusion protein comprising the YebF variant, is

secreted into the medium, by the methods disclosed in the Materials and Methods, and Examples disclosed herein. Modifications of protein properties such as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, or the tendency to aggregate with carriers or into multimers may be assayed by methods well known to one of skill in the art.

Variants may be created experimentally using random mutagenesis, oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis and cassette mutagenesis. Oligonucleotide-mediated mutagenesis is well known in the art as, for example, described by Adelman<sup>31</sup> using vectors that are either derived from bacteriophage M13, or that contain a single-stranded phage origin of replication as described by Viera et al.<sup>32</sup> Production of single-stranded template is described, for example, in Sambrook.<sup>17</sup> Alternatively, the single-stranded template may be generated by denaturing double-stranded plasmid (or other DNA) using standard techniques.

Alternatively, linker-scanning mutagenesis of DNA may be used to introduce clusters of point mutations throughout a sequence of interest that has been cloned into a plasmid vector. For example, reference may be made to Ausubel.<sup>33</sup> Region-specific mutagenesis and directed mutagenesis using PCR may also be employed to construct variants according to the invention. In this regard, reference may be made, for example, to Ausubel.<sup>33</sup> With regard to random mutagenesis, methods include incorporation of dNTP analogs<sup>34</sup> and PCR-based random mutagenesis such as described in Stemmer and Shafikhani.<sup>35,36</sup>

The term "biologically active" when made in reference to a variant or portion of YebF, refers to a protein, polypeptide or peptide possessing at least the secretory function of YebF. A biologically active variant or portion of YebF has at least about 5%, preferably at least about 25%, more preferably at least about 50% and most preferably at least about 75% of the secretory activity of YebF. Whether the variant or portion of the YebF protein has secretory activity may be determined, for example, by the methods disclosed in the Materials and Methods, and Examples disclosed herein. A biologically active variant or portion of YebF may either be secreted into the growth medium, or may effect the

secretion a fusion protein (of which it comprises part) into the growth medium, and both of these activities are considered to be a secretory activity.

The term "portion" when used in reference to a protein refers to fragments of that protein. The fragments may range in size from four amino acid residues to the entire amino acid sequence of the protein, minus one amino acid.

A "peptide" is polymer of four to 20 amino acids, a "polypeptide" is a polymer of 21 to 50 amino acids and a "protein" is a polymer of more than 50 amino acids.

A fusion protein is a recombinant protein comprising regions derived from at least two different proteins. The term "fusion protein" as used herein refers to a protein molecule in which a protein, polypeptide or peptide of interest is fused to: YebF, a biologically active variant of YebF, or a biologically active portion of YebF (herein a "YebF, or a biologically active variant or portion thereof"). "Fused", in one context means that nucleic acid encoding YebF, or a biologically active variant or portion thereof, is joined in frame to the nucleic acid encoding the protein, polypeptide or peptide of interest, to provide for a single amino acid chain when transcription and translation occur. In another context, "fused" may also be a reference to the joining of a protein, polypeptide or peptide of interest to YebF, or a biologically active variant or portion thereof.

A "secreted fusion protein" is the part of the fusion protein that is secreted into the bacterial growth medium. As is apparent, a secreted fusion protein will likely lack the amino acids that comprise the leader sequence of YebF, specifically MKKRGA FLGLLLVSAC ASVF (SEQ ID NO: 20).

An "expression vector" refers to a recombinant DNA molecule containing the appropriate control nucleotide sequences (*e.g.*, promoters, enhancers, repressors, operator sequences and ribosome binding sites) necessary for the expression of an operably linked nucleotide sequence in a particular host cell. By "operably linked/linking" or "in operable combination" is meant that the nucleotide sequence is positioned relative to the control nucleotide sequences to initiate, regulate or otherwise direct transcription and/or the synthesis of the desired protein molecule.

The expression vector may be self-replicating, such as a plasmid, and may therefore carry a replication site, or it may be a vector that integrates into a host chromosome either randomly or at a targeted site. The expression vector may contain a selection gene as a selectable marker for providing phenotypic selection in transformed cells. The expression vector may also contain sequences that are useful for the control of translation.

"Purified" or "to purify" refers to the removal of undesired components from a sample. For example, to purify the secreted fusion protein from the bacterial growth medium, may mean to remove other components of the medium (*i.e.*, proteins and other organic molecules) thereby increasing the percentage of the secreted fusion protein.

The present invention utilizes YebF, or a biologically active variant or portion thereof, to direct the secretion of a protein, polypeptide or peptide of interest, into the bacterial growth medium. This may be accomplished by generating a fusion protein, which comprises YebF or a biologically active variant or portion thereof, and the protein, polypeptide or peptide of interest.

A recombinant DNA molecule that encodes the fusion protein can be made, for example, by ligating a nucleic acid that encodes the protein, polypeptide or peptide of interest (a nucleotide sequence of interest), in frame, to a nucleic acid that encodes the YebF protein, or a biologically active variant or portion thereof. In one embodiment, the nucleic acid that encodes the protein, polypeptide or peptide of interest may be ligated to the 3'-end (*i.e.*, downstream) of the nucleic acid that encodes the YebF protein, or a biologically active variant or portion thereof. In another embodiment, the nucleic acid that encodes the protein, polypeptide or peptide of interest may not be ligated directly to the 3'-end of the YebF protein, or a biologically active variant or portion thereof. Rather, a spacer nucleotide sequence may separate the 3'-end of the nucleotide sequence encoding the YebF protein, or a biologically active variant or portion thereof, and the 5'-end of the nucleotide sequence that encodes the protein, polypeptide or peptide of interest. The spacer nucleotide sequence encodes one or more amino acids that may or may not be functional (*i.e.*, a tag, or a cleavage site, or no function at all but to separate the two parts). Therefore, in the fusion protein produced by these embodiments, the protein, polypeptide or peptide of interest is located carboxy-terminally to the YebF protein, or a biologically active variant or portion thereof. Methods of generating this recombinant DNA molecule

are known to those of skill in the art, examples of which are provided by the methods disclosed in the Materials and Methods, and Examples disclosed herein, or the references cited herein.

The nucleotide sequence that encodes the YebF protein, or a biologically active variant or portion thereof, or the nucleotide sequence that encodes the protein, polypeptide or peptide of interest may additionally comprise transcriptional and translational control regions, which are short arrays of DNA sequences that interact specifically with cellular proteins involved in transcription and translation. These regions include promoters, operator sequences and ribosome binding sites, and are known to those of skill in the art.

It may also be desirable to tag the fusion protein or the secreted fusion protein with at least one tag that may be useful for purifying the secreted fusion protein from the growth medium, for identifying the secreted fusion protein, or for some other purpose. Useful tags include epitope tags that are recognized by a specific antibody, thereby permitting the fusion protein to be purified by affinity chromatography, or to be identified, for example with a fluorescent antibody. Examples of a useful eptiopes are: glutathione-S-transferase, *c-myc*, poly-histidine, FLAG®, maltose binding protein, influenza A virus haemagglutinin,  $\beta$ -galactosidase and GAL4, or portions thereof. Preferred may be a polyhistidine (poly-His tag). Cognate antibodies that recognize these epitope tags are known to those of skill in the art. For example, polyhistidine is recognized by an anti-His Mab available from Qiagen, FLAG® is recognized by Anti-FLAG M1, M2 and M5 Mabs, available from Sigma/Kodak. Therefore, contemplated herein may be the inclusion, in the recombinant DNA molecule, of at least one nucleotide sequence that encodes a tag amino acid sequence. The tag may be anywhere on the fusion protein, with the possible exception of at the amino-terminal end, or in the leader sequence, of the YebF protein, or a biologically active variant or portion thereof.

It may also be desirable to later cleave the secreted fusion protein, in order to separate the YebF portion (*i.e.*, the mature YebF protein, or a biologically active variant or portion thereof) and/or the tag, from the protein, polypeptide or peptide of interest. For example, if the YebF portion and/or tag interferes with the biological activity of the protein, polypeptide or peptide of interest, it may be preferred to cleave either or both of them from the fusion protein. Therefore, contemplated herein may be the inclusion, in the

recombinant DNA molecule, of at least one nucleotide sequence that encodes an amino acid sequence, which amino acid sequence facilitates the cleavage of the YebF portion and/or epitope tag and/or the protein, polypeptide or peptide, from the fusion protein. Examples of suitable amino acid sequences for cleavage by specific proteases are: (a) Factor Xa Protease- recognizes the amino acid sequence Ile-Glu-Gly-Arg and cleaves the peptide bond C-terminal of the arginine residue<sup>24,25</sup>; (b) Tobacco Etch Virus (TEV) NIa protease- recognizes a seven amino acid consensus sequence, Glu-X-X-Tyr-X-Gln/Ser, where X can be various amino acid residues, and cleaves between the conserved Gln and Ser residues<sup>26</sup>; (c) PreScission™ Protease- cleaves between the Gln and Gly residues of the recognition sequence of LeuGluValLeuPheGln/GlyPro<sup>27,28</sup>; (d) Thrombin – which is used to digest fusion proteins prepared from pGEX vectors (GST Gene fusion) containing the recognition sequence for thrombin<sup>29</sup>, and (e) Enterokinase – which cleaves after lysine at its cleavage site Asp-Asp-Asp-Asp-Lys, or other basic residues, depending on the conformation of the protein substrate<sup>30</sup>.

Therefore, a recombinant DNA molecule contemplated herein comprises a nucleotide sequence that encodes the YebF protein, or a biologically active variant or portion thereof and a nucleotide sequence that encodes the protein, polypeptide or peptide of interest, and optionally at least one nucleotide sequence that encodes a tag, and/or optionally at least one nucleotide sequence that encodes a protein cleavage site. These various nucleotide sequences are in frame with one another. Therefore, the fusion protein and secreted fusion protein contemplated herein comprise optionally, at least one tag and/or optionally at least one cleavage site.

The resultant recombinant DNA molecule may then be inserted into an expression vector. Useful vectors for practicing the invention disclosed herein are plasmids, for example pMS119EH, which comprises a *lac* promoter, and pT7-5, which comprises a T7 promoter. The expression vector selected will depend on which bacterial strain or species is to be used to express the fusion protein.

As is apparent to those of skill in the art, the above sequence of events need not be practiced in the above order, nor need the above methods be used, in order to generate the expression vector comprising the recombinant DNA molecule. For example, the nucleic

acid that encodes the protein, polypeptide or peptide of interest may be inserted into the expression vector, followed by the insertion of the nucleic acid that encodes the YebF protein, or a biologically active variant or portion thereof, or vice versa (see Materials and Methods, herein). A nucleic acid that encodes the tag or the protein cleavage site, if used, may be inserted before or after either of the above components of the recombinant DNA molecule are inserted into the expression vector. The expression vector may already comprise a nucleic acid that encodes a tag sequence, obviating the need to add this component separately (see Materials and Methods, herein).

The expression vector comprising the recombinant DNA molecule is then transfected into the appropriate bacterial host, for expression of the fusion protein. Examples of how this can be accomplished are provided examples provided in the Materials and Methods, and Examples herein. As non-limiting examples, the expression vector may be transfected into HB101, BL21 or MG1655. For example, pMS119EH comprising an insert can be used in HB101 or MG1655, and pT7-5 comprising an insert can be used in BL21.

Preferred for use herein may be an expression vector that replicates extrachromosomally, as a greater number of copies of the fusion protein nucleic acid construct can be generated, which will generally result in higher levels of expression and hence secretion.

The present invention contemplates the secretion of many different proteins, polypeptides or peptides of interest. Contemplated herein are peptides as small as 4 amino acids. Also contemplated herein is any protein or polypeptide that can be secreted by the methods disclosed herein, regardless of the size. In the Examples provided, a protein of 48 kD was secreted, suggesting that large proteins can readily be secreted by the method disclosed herein.

Both hydrophilic and hydrophobic proteins may be secreted by the method disclosed herein. In the Examples provided both a hydrophobic protein (hIL2) and a hydrophilic protein ( $\alpha$ -amylase or alkaline phosphatase) were secreted.

The bacterial cells are grown in growth medium, such as terrific broth, until such time as is desired to harvest the secreted fusion protein from the medium. The time required depends upon a number of factors relating to the bacterial expression system being used and to the fusion protein being produced. The rate of growth of a particular bacterial



strain or species, the rate at which the secreted fusion protein accumulates in the medium, the stability of the secreted fusion protein in the medium, and the time at which bacterial lysis begins to occur (which will contaminate the growth medium) are non-limiting examples of the types of considerations that will affect when the secreted fusion protein is harvested from the culture medium.

Depending upon the level of purity required, which will again depend upon the application for which the secreted fusion protein will be used, the secreted fusion protein may be further purified, for example by affinity chromatography. If desired, the YebF portion and/or the tag may be cleaved from the secreted fusion protein, in order to generate the protein, polypeptide or peptide of interest, alone.

Disclosed herein is the fact that YebF can be used to direct the secretion of proteins, polypeptides and peptides, as fusion proteins, into the medium. The inventors have cloned three different nucleotide sequences of interest into a vector that comprises the nucleotide sequence for *yebF*. Accordingly, disclosed herein is an expression vector that comprises a nucleic acid encoding YebF operatively linked to control nucleic acid sequences needed to initiate, regulate or otherwise direct transcription and the synthesis of YebF. The expression vector may comprise restriction endonuclease sites, or other sites, downstream of the YebF coding region, useful for easy in frame insertion of a nucleic acid encoding a protein, polypeptide or peptide of interest. The expression vector may also comprise a tag nucleotide sequence, as shown in the Materials and Methods herein, or a nucleotide sequence encoding a protein cleavage site.

Also disclosed herein is the fact that the leader sequence of YebF may be used to direct the transport of a protein into the periplasm. Accordingly, disclosed herein is an expression vector that comprises a nucleic acid encoding the leader sequence of YebF operatively linked to control nucleic acid sequences needed to initiate, regulate or otherwise direct transcription and the synthesis of the YebF leader sequence. The expression vector may comprise restriction endonuclease sites, or other sites, downstream of the YebF leader coding region, useful for easy in frame insertion of a nucleic acid encoding a protein, polypeptide or peptide of interest. The expression vector may also comprise a tag nucleotide sequence, as shown in the Materials and Methods herein, or a nucleotide sequence encoding a protein cleavage site. Also disclosed herein is the use of the YebF

leader sequence to direct transport of a protein, peptide or polypeptide to the periplasm. Also disclosed herein is a method for expressing a protein, polypeptide or peptide of interest in the periplasm, which method comprises providing an expression vector that encodes a protein comprising the protein, polypeptide or peptide of interest located carboxy-terminally to YebF leader sequence, and expressing the protein in a suitable bacterial cell.

While the invention has been described in conjunction with the disclosed embodiments, it will be understood that the invention is not intended to be limited to these embodiments. On the contrary, the invention is intended to cover alternatives, modifications and equivalents, which may be included within the spirit and scope of the invention as defined by the appended claims. Various modifications will remain readily apparent to those skilled in the art. Examples provided above and below are not intended to be limited to those examples alone, but are intended only to illustrate and describe the invention rather than limit the claims that follow.

## EXAMPLES

### Materials and Methods

**Bacterial strains and growth conditions:** The *E. coli* strains used in this study were HB101 (*supE44 hsd20(r<sub>B</sub><sup>-</sup>m<sub>B</sub><sup>-</sup>) recA13 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5 mtl-1*), BL21(DE3)(*hsdS gal(λcIts857 ind1 Sam7 nin5 lacUV5-T7 gene 1)*), and MG1655(*F- λ-ilvG- rfb-50 rph-1*). Cells were grown at 30°C in Terrific broth (TB). Antibiotics were added at the following concentrations: 100 µg/ml of ampicillin (Amp) and 80 µg/ml chloramphenicol (Cm). Expression of genes under *lac* promoter control was induced with 0.1mM isopropyl-µ-D-thiogalactopyranoside (IPTG).

**Molecular biology techniques and plasmid construction:** DNA manipulation, sequencing and bacterial transformation were essentially as described<sup>17</sup>. Expression plasmids were constructed based on pMS119EH<sup>18</sup> containing the *lac* promoter, or pT7-5 with the T7 promoter. PCR amplifications using the touch-down protocol and DNA purification thereafter were carried out as described<sup>19</sup>.

The *yebF* gene was amplified from HB101 chromosomal DNA using the following forward and reverse oligomers, respectively, with the indicated restriction sites underlined: *yebF*5, 5'-GAGAATTCGAGAAAAACATGAAAAAAG-3' containing *EcoR*I (SEQ ID NO: 4); and *yebF*3, 5'-ATATCTCGAGACGCCGCTGATATTC-3 (*Xho*I) (SEQ ID NO: 5). To tag the gene with 6 histidines at its 3'-end (*yebFH*<sub>6</sub>), the amplified DNA, after digestion with *EcoR*I and *Xho*I, was cloned into pCITE-2a(+) (Novagen, US) cut with the same enzymes. The *EcoR*I- *Hind* III fragment carrying *yebFH*<sub>6</sub> was then subcloned into pMS119EH to generate pYebFH<sub>6</sub>/MS, or into pT7-5 to make pYebFH<sub>6</sub>/T7.

The mature truncated form of the  $\alpha$ -amylase gene (GenBank accession no. AB015592) of *Bacillus subtilis* X-23<sup>4</sup> was amplified from pAC92 kindly provided by Dr. Spartaco Astolfi-Filho, University of Brasilia, Brazil using the following oligos: amy5, 5'-TAGAATTCAGGAGAAAAACATGGTCTCGACTCGGTCA AAAACGGG-3' (SEQ ID NO: 6) engineered with an *EcoR*I site, a ribosomal binding site (bold), the in-frame initiation codon ATG and *Sal*I; amy3, 5'-ATATCTCGAGATGAGGCGCATT TCC-3 (*Xho*I) (SEQ ID NO: 7). The amplified DNA was cut with *EcoR*I and *Xho*I and replaced the *yebF* fragment (*EcoR*I-*Xho*I) in pYebFH<sub>6</sub>/MS to create pAmyH<sub>6</sub>.

pYebF-AmyH<sub>6</sub> containing the *yebF*-*amy* fusion gene was created by replacing the *EcoR*I-*Sal*I fragment in pAmyH<sub>6</sub> with the *EcoR*I-*Xho*I fragment carrying the *yebF* gene from pYebFH<sub>6</sub>/MS. Between the *yebF* nucleotide sequence and the *amy* nucleotide sequence, there is encoded an additional two amino acids- LE- which will link the two proteins.

To fuse the *sec*-leader sequence of the *yebF* gene to the mature  $\alpha$ -amylase gene, the leader sequence was first amplified by PCR using pYebFH<sub>6</sub>/MS as the template with Fls (5'-ATATCTCGAGAGCGAAACTGATGC-3') (SEQ ID NO: 8) containing an *Xho*I restriction site and *yebF*5 (above) as the oligomers. After digestion with *EcoR*I and *Xho*I, the amplified DNA fragment was inserted into pAmyH<sub>6</sub> to replace the *EcoR*I- *Sal*I sequence, which generated pLS-AmyH<sub>6</sub>. The sequence of this hybrid gene was verified by sequencing.

To construct pYebF-hIL2H<sub>6</sub>, the hIL-2 gene was amplified by PCR from pBM806, a plasmid containing an hIL-2 gene provided by Biomira Inc. (Edmonton, Canada) using the following oligonucleotides: hil5 with *Sal*I, GATCATGTCGACGCTCCGACCTCCAGC (SEQ ID NO: 9) and hil3 with *Xho*I, ATATCTCGAGGGTCAGGGTGGAGAT (SEQ ID

NO: 10). The *Sall*-*Xho*I fragment of the PCR product was inserted into *Xho*I site in pYebFH6/MS to generate pYebF-hIL2H<sub>6</sub>. Between the *yebF* nucleotide sequence and the *hIL-2* nucleotide sequence, there is encoded an additional two amino acids- LE- which will link the two proteins, which is then followed by the six histidine residues as the tag.

The amino acid sequence of mature hIL-2 (*i.e.*, lacking the 20 amino acid leader sequence) is:

```
APTSSSTKKT QLQLEHLLLD LQMILNGINN YKNPKLTRML TFKFYMPKKA
TELKHLQCLE EELKPLEEVL NLAQSKNFHL RPRDLISNIN VIVLELKGSE
TTFMCEYADE TATIVEFLNR WITFCQSIIS TLT (SEQ ID NO: 11)
```

To make pYebF-phoAH<sub>6</sub>/T7 plasmid, the *phoA* gene was PCR-amplified with the following oligos: phoA5 with *Xho*I, GCATATCTCGAGCGGACACCAGAAATGCC (SEQ ID NO: 12); and phoA3 with *Sal*I, CGATAGTCGACTTTCAGCCCCAGAGC (SEQ ID NO: 13). The *Xho*I-*Sal*I fragment of the PCR product was inserted into *Xho*I site in pYebFH<sub>6</sub>/T7 to generate pYebF-phoAH<sub>6</sub>/T7.

**Protein expression and treatment of samples:** A single colony from LB plates or a small aliquot of cold cell suspension stored in 40% glycerol at -20°C was inoculated into 1.5 ml of TB and grown overnight at 30°C. After harvesting by centrifugation the cells were washed once in 1.5 ml of fresh TB, and were suspended in 1.5 ml of fresh TB and inoculated at 1% by volume into fresh TB for expression studies. Protein expression was induced by addition of 0.1mM IPTG or 0.5 mM IPTG at 0.6 OD<sub>600</sub>. Cells were harvested at the indicated time points in the experiments. After harvesting by centrifugation at room temperature to avoid cold shock, cell pellets were washed once with a volume equal to the original culture volume of 100 mM MOPS (pH7.0). The resulting medium supernatant was filtered using a 0.22 µm Millipore filter to remove un-pelleted cells.

**Subcellular fractionation:** Periplasm was separated from cytoplasm by the osmotic shock method.<sup>21</sup>

**α-amylase activity assay:** This assay is based on the 3,5-dinitrosalicylic acid method as described by Ohdan *et al.*<sup>8</sup> using starch as the substrate for the enzyme. The reaction was stopped by adding 200 µl of DNSA in 0.4N NaOH to 200 µl of the reaction mixture after

10 minutes incubation at 58°C with shaking once per minute. The mixture was boiled for 5 minutes thereafter, diluted with 1 ml of water, and spun for 1 minute to pellet starch. Finally, readings were taken at 540nm. The enzyme activity was expressed in moles of glucose released per minute that is equivalent to the amount of reducing sugar released by the enzyme from starch in the reaction. A pair of every sample to be assayed was set up. One is for the reaction, the other for background reading, to which 200 µl of DNSA was added before the reaction starts.

To measure the activity in the medium or in the osmotic shock fluid, the liquid was directly added to the reaction mixture. To assay the activity in cells or in the resulting spheroplasts from the osmotic shock, the cell suspension or the spheroplast suspension in 10mM Tris-HCl (pH7.0) was mixed with equal volume of lysis buffer (pH 8.0) consisting of 70 µg/ml lysozyme, 6 mM EDTA, 2% Triton X-100 to break cells or spheroplasts. After lysis was complete on ice, 1 µl of 210 mM CaCl<sub>2</sub> was added to every 70 µl of the lysate to overcome the EDTA and allow for 0.1mM Ca<sup>2+</sup> in the reaction mixture as required for α-amylase activity.

**Alkaline phosphatase activity assay:** 1 ml of the reaction consists of 100mM Tris-HCl (pH8.0), 10mM MgCl<sub>2</sub>, 2mM ZnCl<sub>2</sub> and 0.04% pNPP. The reaction after incubation of indicated period was stopped by addition of 40 µl of 5M NaOH followed by 1 minute of centrifugation at 14,900rpm before taking readings at 410nm. To measure the background readings, samples were added to the mixtures after the reactions were stopped by NaOH. To calculate the enzyme activities,  $\epsilon_{410} = 17,800 \text{ M}^{-1} \text{ cm}^{-1}$  for *p*-nitrophenolate anion (pNP), the yellow product released from pNPP.

**Purification of YebFH<sub>6</sub> and protein chemistry:** Total protein in the culture medium of *E. coli* HB101/pYebFH<sub>6</sub>/MS grown overnight (15 hr) after induction with IPTG was precipitated by ammonium sulfate at 70% saturation at 4°C in the presence of 0.2 mM PMSF. The pellet was dissolved in 20 mM Tris-HCl (pH7.5) containing 0.2mM PMSF, 10 mM imidazol and 500 mM NaCl. Purification of YebFH<sub>6</sub> was achieved using a nickel affinity column (Amersham). This partially purified protein was further purified using a reversed-phase HPLC on a 300Å C8 column (1mm x 15 cm) eluted with a gradient of acetonitrile from 0% to 2% in the presence of 0.05% TFA at the flow rate of 100 µl/min. A single major peak was observed at the 25th min. This peak fraction was collected and

used for both MALDI-TOF linear mode mass spectrometry (Voyager 6064, Applied Biosystems) and N-terminal amino acid sequence determination using Routine 3.0 on a Hewlett Packard G1000A Protein Sequencer.

**Protein electrophoresis and Western blotting:** The protein samples from either the culture medium or the cells were prepared by precipitation with 5% trichloroacetic acid (TCA). After centrifugation in an Eppendorf tube at 14,900 rpm at room temperature for 5 minutes, the pellet was washed once by suspending it in 1 ml of water and centrifuging for 5 minutes to remove residual TCA. To almost completely extract TCA from the pellets, 1.5 ml of  $-20^{\circ}\text{C}$  cold acetone was added to each tube. The tube was then vortexed and kept at  $-20^{\circ}\text{C}$  for 20 minutes before centrifugation as above. The pellet was retained and subjected to one additional acetone wash. The final pellet was dissolved in 50 mM Tris-HCl, pH 8.0 before adding an equal volume of electrophoresis loading buffer. Proteins were separated on 8.5% SDS-Tricine gel<sup>22</sup> and then transferred to a nitrocellulose membrane for immunoblotting. To detect the histidine tag, monoclonal mouse antibody against histidine tag (Qiagen) was used. CRP was detected using a rabbit polyclonal antiserum against CRP, kindly provided by Dr. Hiroji Aiba, Nagoya University, Japan. Immunoblots were developed by enhanced chemiluminescence using the ECL kit (Amersham).

**IL-2 bioassay:** The biological assay of YebF-hIL2 was based on the Lei *et al.* method<sup>23</sup> using the IL-2 dependent T lymphocyte cell line CTLL-2 with modifications. Prior to the assay, the YebF-hIL2 sample was prepared by passing the *E. coli* culture medium harvested 3 hours after induction with 0.1mM IPTG from either HB101/pYebF-hIL2H<sub>6</sub> or pMS119EH (control) through a 0.22  $\mu\text{m}$  Millipore filter. The cell culture medium (RHFM) for CTLL-2 uses RPMI 1640 supplemented with 10% (v/v) fetal calf serum, 0.1 mM  $\beta$ -mercaptoethanol, 25mM HEPES pH7.5, 2 mM L-glutamine. 50  $\mu\text{l}$  of fresh CTLL-2 cells ( $10^6$  cells/ml) in RHFM were placed in a well of a 96-well plate. 50  $\mu\text{l}$  of standard hIL-2 (kindly provided by Dr. C. Bleackley, University of Alberta) or YebF-hIL2 samples diluted with RHFM was added. The cells were incubated at  $37^{\circ}\text{C}$  with 5%  $\text{CO}_2$  for 20 hours. Cell proliferation was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay. 5 mg of MTT/ml was prepared in phosphate buffered saline and sterilized. 10  $\mu\text{l}$  of MTT was added to each well followed by 4 hours incubation at  $37^{\circ}\text{C}$ . 150  $\mu\text{l}$  of isopropanol containing 0.04N HCl was added to each well

and mixed thoroughly with a pipettor to dissolve the resulting crystals. The absorbance was read at 560 nm. Each value is the average of three assays.

### Characterization of the *E. coli* YebF leader

Examination of the DNA sequence of the *yebGFE* operon revealed a typical ribosome-binding site (GGAG, Blattner coordinates 1928421 – 1928424 in MG1655) upstream from the second ATG (1928412 – 1928414) in the region between *yebG* and *yebF*. Although the first ATG (Blattner coordinates 1928424 – 1928426) could initiate in-frame translation of YebF, and this is the way it is reported in databases such as NCBI (B1847) and Swiss-Prot (P33219), no ribosome-binding site could be found preceding this ATG. The *yebF* gene was cloned in the expression vector pMS119EH under *lac* promoter control starting from nucleotide G (Blattner coordinate 1928424) without addition of a ribosome binding site and with the addition of a 6-histidine tag at the carboxyl terminus. The His-tagged YebF protein was positively expressed as shown by immunoblotting (see below).

The N-terminal amino acid sequence of *E. coli* YebF is as follows:

(-21)MKKRGAFLLGLLLVSACASVFA(-1) (1)ANNE....

This sequence resembles the motif characteristic of lipoproteins<sup>4</sup>, including the fatty acid-acylation site (Cys-6). This motif is also conserved in YebF from *Shigella flexneri* (97% identity). However, this Cys is missing in other similar proteins such as STY2087 from *Salmonella typhi* (77% identity), YebF from *Salmonella typhimurium* (76% identity), YP01779 from *Yersinia pestis* (43% identity) and PLU2692 from *Photobacterium luminescens* (40% identity). Therefore, YebF may not be a lipoprotein as suggested in several databases (B1847 at NCBI and P33219 at Swiss-Prot). The amino terminal sequence of the *E. coli* YebF protein also contains a typical 21 amino acid *sec*-leader peptide including 3 basic residues (-20 Lys-Lys-Arg-18) at the N-terminal end, followed by a 16 residue long hydrophobic core and a small residue (Ala-1) which could serve as the leader peptidase I cleavage site (Fig.1). A similar leader sequence was found in all YebF related proteins (Fig.1) suggesting that *E. coli* YebF may be secreted to the periplasm.

### **YebF localization**

To determine where YebF was localized, a 200 ml culture of HB101/pYebFH<sub>6</sub>/MS was grown in TB at 30°C until the optical density at 600 nm reached 0.6. The culture was induced with 0.1 mM IPTG and harvested 4 hours after induction and washed once at room temperature with 200 ml of 100 mM MOPS (pH7.0). Cells were subjected to cold osmotic shock (Neu and Heppel, 1965) to separate periplasm from the cytoplasm. Protein samples from these resulting fractions and immunoblotting were prepared as described in Materials and Methods.

YebF was located in the periplasm and surprisingly also in the culture medium. No YebF was detected in the spheroplasts after cold osmotic shock (Fig. 2A).

To determine the effect of inhibition of protein synthesis on secretion, 10 ml HB101/pYebFH<sub>6</sub>/MS cells were grown as described for Fig. 2A. After harvesting, cells were washed once with 35 ml of fresh TB and suspended in 10 ml of fresh TB containing 80 µg chloramphenicol/ml. 1.5 ml of cells were taken at the time points indicated in Fig. 2B. Cells and medium were separated by centrifugation at room temperature to avoid cold shock. Immunoblotting was conducted as described in the Materials and Methods using a monoclonal antibody directed against the His<sub>6</sub> tag.

When protein synthesis was inhibited, the level of YebF in the periplasm gradually declined to a trace level while it progressively accumulated in the medium during the subsequent incubation period (Fig. 2B).

To demonstrate that YebF protein accumulates in the medium during growth, cells were induced with 0.1 mM IPTG, grown overnight, collected at the indicated time after induction and prepared as described in the Materials and Methods. As can be seen in Fig. 3, all the YebF was located in the culture medium.

When cells were induced and grown overnight, all the YebF was located in the medium (data not shown). Taken together, this data suggested that YebF is most likely an extracellular, soluble protein (see below).



### Characteristics of the secreted YebF

The secreted YebF-His<sub>6</sub> in both the periplasm and culture medium migrated on SDS-Tricine polyacrylamide gels at a molecular weight corresponding to the mature His-tagged protein (~12 kD) (Fig. 3). YebF-His<sub>6</sub> was purified from the culture medium as described in the Materials and Methods and N-terminal amino acid sequence analysis revealed the sequence to be Ala-Asn-Asn-Glu-Thr-Ser-Lys-Ser-Val-Thr. This result indicates that YebF is cleaved immediately after the 21-amino acid *sec*-leader and not preceding the Cys at position -6 (Fig. 1). To examine whether there were any fatty acids bound to the mature YebF protein, the mass was determined to be 11,829.2 $\pm$ 1.4 Daltons by Maldi-TOF linear mode mass spectrometry (Fig. 4). The calculated mass of mature His-tagged YebF with the 6-histidine tag and Leu-Glu linking amino acids, was 11,860.3 Daltons. This is 31.1 Daltons (0.26%) larger than the experimentally determined mass. If there were any covalently attached fatty chains, the mass determined by mass spectrometry would be expected to be larger than the calculated mass, suggesting therefore that YebF is not a lipoprotein.

### Secretion of YebF into the medium

The presence of YebF in the culture medium could be a result of cell lysis, leakage through the outer membrane, a natural cell secretion process or some combination. To test for lysis, immunoblotting was used to compare the subcellular localization of YebF and catabolite repressor protein (CRP), a well-known DNA binding protein residing in the cytoplasm. *E. coli* HB101/pYebFH<sub>6</sub>/MS was grown in 50 ml of TB at 30°C until OD<sub>600</sub> reached 0.6 and induced with 0.1 mM IPTG. Ten ml of cell culture was harvested at 2, 4 and 6 hours after induction. The cells were washed once in 10 ml of 100 mM MOPS and suspended in 10 ml of the same MOPS buffer. The medium was filtered through a 0.22  $\mu$ m Millipore filter. Both cell suspension and medium were mixed with 2.5 ml of 25% trichloroacetic acid (TCA) to precipitate proteins. TCA trapped in the pellets was removed by two extractions using -20°C acetone. Protein samples were loaded onto two parallel gels which were subsequently subjected to immunoblotting.

In cells, both CRP and YebF were readily detected. In the medium, YebF was detected at all experimental time points (Fig. 5A). CRP, however, was not observed in the medium at 2 and 4 hours after induction (Fig. 5B). A trace amount of CRP was detected at 6 hours,

which indicates the beginning of inevitable cell lysis (Fig. 5). This indicates that the YebF found in the medium up to 4 hours post induction did not result from cell lysis.

In order to investigate the possible involvement of outer membrane leakage, two chimeric genes were constructed in the vector pMS119EH, under *lac*-promoter control, by fusing the leaderless, mature  $\alpha$ -amylase gene from *Bacillus subtilis*<sup>9</sup> to either the 3' end of the *yebF* gene (pYebF-AmyH<sub>6</sub>) or directly to the *sec*-leader sequence of *yebF* (pLS-AmyH<sub>6</sub>). In addition, the leaderless mature  $\alpha$ -amylase gene in the same vector (pAmyH<sub>6</sub>) was used as a control. The mature  $\alpha$ -amylase without any signal sequence should remain in the cytoplasm. Cells were grown in HB101 and induced as in Fig. 2. Cells were harvested 4 hours after induction with 0.1mM IPTG, prior to any cell lysis and subjected to cold osmotic shock<sup>21</sup> and  $\alpha$ -amylase activity quantitated as described in Materials and Methods.

HB101 cells with pMS119EH produced an undetectable level of  $\alpha$ -amylase either in the medium or in the cells (data not shown). Only  $\alpha$ -amylase fused to full-length YebF could be found in the medium with 35% of the total activity in the medium. The leaderless  $\alpha$ -amylase and  $\alpha$ -amylase fused to the leader peptide of YebF were expressed but remained inside cells, and less than 5% of each on average were detected in the medium (Fig.6A). These data were confirmed by the protein profile in the medium shown in Fig. 6B.

Using the cold osmotic shock method, the periplasm of cells was separated from the cytoplasm. As shown in Fig.6A, over 68% of the  $\alpha$ -amylase fused to the leader of YebF was recovered in the periplasm. 85% of leaderless  $\alpha$ -amylase remained in the cytoplasm. 12 % of the leaderless  $\alpha$ -amylase found in the periplasm could be due to cell breakage during the cold osmotic shock. These data demonstrated that the YebF leader was able to direct the fusion protein from the cytoplasm to the periplasm using the *sec*-dependent translocation system but could not release the protein to the medium. Therefore these data together with the absence of  $\alpha$ -amylase in the medium from cells harboring plasmid pLS-AmyH<sub>6</sub> indicate that the outer membrane was able to prevent mature  $\alpha$ -amylase (the YebF leader peptide was removed by leader peptidase I) from leaking out of cells during normal growth.

The YebF- $\alpha$ -amylase fusion protein was able to cross the outer membrane from the periplasm (Fig 6A). This demonstrates that YebF played an essential role in targeting the fusion protein for secretion across the outer membrane to the medium. In addition, Fig. 2

shows no apparent difference in the mobility of YebF protein in the periplasm or in the culture medium. This indicates that no additional cleavage occurred during secretion across outer membrane. This is also supported by the coincidence of the molecular weight calculated from the sequence (11,860 dalton) with that determined by mass spectrometry (11,829 dalton).

To further demonstrate that the presence of YebF in the medium is due to secretion from cells, rather than periplasmic leakage, the release of YebF- $\alpha$ -amylase was compared to the release of alkaline phosphatase, an endogenous well-defined periplasmic enzyme, in GZ39T/pYebF-AmyH<sub>6</sub> cells. Because alkaline phosphatase is induced by phosphate-starvation, it is very poorly expressed in wild-type *E. coli* cells grown in rich medium containing inorganic phosphate salts. To overcome this, a derivative of TG1, GZ39T, that expresses about 10 times more alkaline phosphatase than TG1 in rich medium, was isolated.

GZ39T/pYebF-AmyH<sub>6</sub> was grown in 25 ml of TB at 30°C. Cells were harvested at 7 hours after induction with 0.05 mM IPTG, washed with 100 mM MOPS (pH7.0) and suspended in 1.5 ml of 30 mM Tris-HCl (pH8.0). 200  $\mu$ l of the cells were mixed with 300  $\mu$ l of cell lysis buffer (see Methods and Materials). This cell lysate was used for both  $\alpha$ -amylase and alkaline phosphatase activity assays. To measure  $\alpha$ -amylase activity in the medium, 35  $\mu$ l of the medium was directly used. To measure alkaline phosphatase activity, 8 ml of the medium was filtered three times through an Amicon ultracentrifugal filter (MWCO 30KD) with 50 mM MOPS (pH7.0) to reduce phosphate and colored substances and finally concentrated to 0.6 ml. 200  $\mu$ l of this preparation was used for the assay (see Methods and Materials). Alkaline phosphatase was assayed at 37°C for 60 minutes in the dark. The results are shown in Fig. 7A, which shows that 42.6% of YebF- $\alpha$ -amylase was secreted to the medium compared to only 5.6% of alkaline phosphatase.

The possibility that over-expression of YebF causes destabilization of the outer membrane was investigated by testing the permeability of 5 antibiotics: erythromycin, rifampicin, vancomycin, bacitracin and azithromycin. Little change in MICs (minimum inhibitory concentrations) was observed for cells expressing YebF or YebF- $\alpha$ -amylase in response to these agents, compared to cells either without plasmid or with pMS119EH (Fig. 7B).

### Secretion capability of different *E. coli* strains

3 ml of cells harboring pYebFH<sub>6</sub>/MS or pYebFH<sub>6</sub>/T7 were grown and induced as in Fig.2A. Protein sample preparation and immunoblotting were conducted as described in the Materials and Methods. Monoclonal antibody against the histidine tag was used to monitor YebF-His<sub>6</sub>.

MG1655 (a K12 strain), BL21(DE3) (a B strain) and HB101 (a hybrid of K12 and B) all secrete YebF into the medium, although the efficiency varied (Fig. 8). This result may suggest that *E. coli* cells including common laboratory strains still possess the capability of secreting proteins including YebF to the surrounding milieu.

### Recombinant protein production with YebF

Fusion protein gene constructs of leaderless  $\alpha$ -amylase of *B. subtilis* X-23<sup>8</sup> (48kD), leaderless *E. coli* alkaline phosphatase (94 kD as a dimer) and the medically relevant protein human interleukin-2 (hIL-2) (15 kD) to the carboxy terminus of YebF were made as described in the Materials and Methods. These represent both hydrophilic ( $\alpha$ -amylase and alkaline phosphatase) and hydrophobic (hIL-2) proteins. All three passenger proteins carried a His<sub>6</sub> tag at their C-terminus.

Cells comprising these fusion protein gene constructs were grown in 25 ml of TB at 30°C. 10 mM DTT was added to one culture at the same time as 0.05 mM IPTG was added to induce expression. Samples were taken 3 hours after induction.

Fig. 9A shows the expression of mature YebF-hIL2 fusion protein in HB101/pYebF-hIL2H<sub>6</sub>. The fusion protein was secreted to the medium at 3 hours after induction under regular growth conditions. With the presence of 10 mM DTT in the medium, however, cells did not secrete the fusion protein to the medium, although comparable expression inside cells was seen. Activity assays for the YebF-hIL-2 fusion protein based on the growth of CTLL-2 T-lymphocytes *in vitro* showed the secreted protein in the medium was active (Fig. 9B). The activity of the fusion protein was 43,800 units of hIL-2/ml of medium.

Fig. 10 shows that by 9 hours after induction 75% of mature YebF- $\alpha$ -amylase fusion protein was secreted from cells. It also appears that the fusion protein was stable in the

medium and the maximal secretion of the YebF- $\alpha$ -amylase occurred after the culture reached stationary phase. From a 1-liter scale experiment, 31 mg of the purified YebF- $\alpha$ -amylase fusion protein with a specific activity of 380.7  $\mu$ mol Glucose/min/mg protein was obtained, using nickel affinity chromatography. The specific activity of  $\alpha$ -amylase in the initial culture medium varies with the time after induction from 150 mol Glucose/min/mg protein at 4 hours to 85 mole Glucose/min/mg protein at 9 hours after induction. It is 3.4  $\mu$ mole Glucose/min/mg protein from *B. subtilis* culture<sup>4</sup>. The high specific activity here is also reflected in the simple protein profile of the medium shown in Fig. 6B.

Mature YebF-alkaline phosphatase fusion protein was also expressed from pYebF-phoAH<sub>6</sub>/T7 plasmid in BL21(DE3) cells under the control of the T7 promoter. 23% was secreted to the medium at 7 hours after induction with IPTG.

## REFERENCES

The following references are cited in the application as numbers in brackets ([ ]) at the relevant portion of the application. Each of these references is incorporated herein by reference.

1. Lomba MR, *et al.* Identification of *yebG* as a DNA damage-inducible *Escherichia coli* gene. *FEMS Microbiol. Lett.* 156: 119-122 (1997).
2. Courcelle J, *et al.* Comparative gene expression profiles following UV exposure in wild-type and SOS-deficient *Escherichia coli*. *Genetics.* 158: 41-64 (2001).
3. van Dyk TK, *et al.* A genomic approach to gene fusion technology. *Proc. Natl. Acad. Sci. USA.* 98: 2555 – 2560 (2001).
4. Brokx SJ, *et al.* Genome-Wide Analysis of Lipoprotein Expression in *Escherichia coli* MG1655. *J. Bacteriol.* 186: 3254 – 3258 (2004).
5. Shokri A, *et al.* Cell and process design for targeting of recombinant protein into the culture medium of *Escherichia coli*. *Appl. Microbiol. Biotechnol.* 60: 654-664 (2003).
6. Pugsley AP and Francetic O Protein secretion in *Escherichia coli* K-12: dead or alive? *Cell Mol. Life Sci.* 54: 347-52 (1998).

7. Errington J and Mountain A Is Bacillus an alternative expression system? In: *Protein production by biotechnology*. Edited by Harris TJR. Elsevier, pp.1-15.(1990).
8. Ohdan K *et al.* Characteristics of two forms of alpha-amylases and structural implication. *Appl. Environ. Microbiol.* 65: 4652-4658 (1999).
9. Poquet I *et al.* Stable periplasmic secretion intermediate in the general secretory pathway of *Escherichia coli*. *EMBO. J.* 12: 271-278 (1993).
10. He SY *et al.* Cloned *Erwinia chrysanthemi* out genes enable *Escherichia coli* to selectively secrete a diverse family of heterologous proteins to its milieu. *Proc. Natl. Acad. Sci. USA.* 88: 1079-1083 (1991).
11. Francetic O, *et al.* Expression of the endogenous type II secretion pathway in *Escherichia coli* leads to chitinase secretion. *EMBO. J.* 19: 6697-703 (2000).
12. Weiner JH, *et al.* A novel and ubiquitous system for membrane targeting and secretion of cofactor-containing proteins. *Cell.* 93:93-101 (1998).
13. Stathopoulos C, *et al.* Secretion of virulence determinants by the general secretory pathway in gram-negative pathogens: an evolving story. *Microbes. Infect.* 2: 1061-1072 (2000).
14. Francetic O and Pugsley AP The cryptic general secretory pathway (*gsp*) operon of *Escherichia coli* K-12 encodes functional proteins. *J. Bacteriol.* 178: 3544-3549 (1996).
15. Robb RJ, Interleukin 2: the molecule and its function. *Immunol. Today* 5:203-209 (1984).
16. Masui Y, *et al.* Microheterogeneity of recombinant products: human interleukin 1 $\alpha$  and 1 $\beta$ . Pp167-172. In: *Curr. Commun. Mol. Biol. – Therapeutic peptides and proteins*. Edited by Marshak D and Liu D. Cold Spring Harbor Laboratory Press, New York (1989).
17. Sambrook J and Russell DW *Molecular cloning, a laboratory manual*. 3<sup>rd</sup> ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (2001).

18. Strack B, *et al.* A common sequence Motif, -E-G-Y-A-T-A-, identified within the primase domains of plasmid-encoded I- and P-type DNA primases and the  $\alpha$  protein of the *Escherichia coli* satellite phage P4. *J. Biol. Chem.* 267: 13062-13072 (1992).
19. Zhang G and Weiner JH CTAB-mediated purification of PCR products. *Biotechniques* 29: 982-986 (2000).
20. Barros E, *et al.*, A novel cloning system for direct screening using a suicidal strategy. *Gene*. 179: 287-289 (1996).
21. Neu, HC and Heppel LA, The release of enzymes from *Escherichia coli* by osmotic shock and during the formation of spheroplasts. *J. Biol. Chem.* 240:3685-3692 (1965).
22. Schagger H and von Jagow G Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. *Anal. Biochem.* 166: 368-379 (1987).
23. Lei H, *et al.* Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-g. *Gene Ther.* 7: 707-713 (2000).
24. Aurell L, *et al.* A New and Highly Specific Chromogenic Substrate for Factor Xa. *Throm. Res.* 11:595-609 (1977).
25. Ellinger S, *et al.* Cleavage of Procaryotically Expressed Human Immunodeficiency Virus Fusion Proteins by Factor Xa and Application in Western Blot (Immunoblot) Assays. *J. Clin. Microbiol.* 27:971-976 (1989).
26. Carrington JC and WG Dougherty A viral cleavage site cassette: identification of amino acid sequences required for tobacco etch virus polyprotein processing. *Proc. Natl. Acad. Sci. USA* 85: 3391-3395 (1988).
27. Walker PA *et al.* Efficient and rapid affinity purification of proteins using recombinant fusion proteases. *Bio/Technology* 12(6):601-5 (1994).
28. Cordingley MG. *et al.* Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. *J. Biol. Chem.* 265(16): 9062-5 (1990).

29. Chang JY *et al.* Thrombin specificity. Selective cleavage of antibody light chains at the joints of variable with joining regions and joining with constant regions. *Eur. J. Biochem.* 151(2): 225-30 (1985).
30. Collins-Racie, LA *et al.* Production of recombinant bovine enterokinase catalytic subunit in *Escherichia coli* using the novel secretory fusion partner DsbA. *Biotechnology*, 13(9): 982-7 (1995).
31. Adelman JP *et al.* In vitro deletional mutagenesis for bacterial production of the 20,000-dalton form of human pituitary growth hormone. *DNA* 2(3):183-93 (1983).
32. Viera *et al.* *Methods Enzymol.* 153: 3 (1987)
33. Ausubel, *Current Protocols in Molecular Biology*, Eds. Ausubel *et al.* (John Wiley & Sons Inc NY) (1995-1999).
34. Zaccolo M *et al.*, An approach to random mutagenesis of DNA using mixtures of triphosphate derivatives of nucleoside analogues. *J. Mol. Biol.* 255(4):589-603 (1996).
35. Stemmer WP DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution *Proc. Natl. Acad. Sci. USA* 91(22):10747-51(1994).
36. Shafikhani S *et al.* Generation of large libraries of random mutants in *Bacillus subtilis* by PCR-based plasmid multimerization. *Biotechniques* 23(2):304-10 (1997).



**CLAIMS**

We claim:

1. A method of producing a protein, polypeptide or peptide of interest that comprises:
  - (a) providing an expression vector that encodes a fusion protein comprising the protein, polypeptide or peptide of interest located carboxy-terminally to YebF, or a biologically active variant or portion thereof, and
  - (b) expressing the fusion protein in a suitable bacterial cell to thereby generate a secreted fusion protein.
2. The method of claim 1, further comprising the step of purifying the secreted fusion protein from the medium in which the bacterial cell is growing.
3. The method of claim 1 or 2, wherein the bacterial cell is *Escherichia coli*.
4. The method of claim 1, 2 or 3, wherein the fusion protein further comprises at least one tag.
5. The method of claim 1, 2, 3 or 4, wherein the fusion protein further comprises at least one protein cleavage site.
6. A method of secreting a protein, polypeptide or peptide of interest from a bacterial cell into the growth medium comprising:
  - a) making an expression vector that comprises a recombinant DNA molecule that further comprises a nucleotide sequence that encodes the protein, polypeptide or peptide of interest joined in frame to a nucleotide sequence that encodes YebF, or a biologically active variant or portion thereof,
  - b) transfecting the expression vector into the bacterial cell, and
  - c) expressing the protein encoded by the recombinant DNA molecule in the bacterial cell under conditions that direct the secretion of the protein into the growth medium.

7. The method of claim 6, wherein the bacterial cell is *Escherichia coli*.
8. The method of claim 6 or 7 wherein the recombinant DNA molecule further comprises at least one nucleotide sequence that encodes a tag.
9. The method of claim 6, 7 or 8 wherein the recombinant DNA molecule further comprises at least one nucleotide sequence that encodes a protein cleavage site.
10. The use of YebF, or a biologically active variant or portion thereof to direct the secretion of a protein, polypeptide or peptide of interest into bacterial growth medium.
11. The use of claim 10, wherein the YebF, or a biologically active variant or portion thereof is part of a fusion protein that further comprises the protein, polypeptide or peptide of interest.
12. The use of claim 10 or 11, wherein the YebF, or a biologically active variant or portion thereof is fused amino-terminally to the protein, polypeptide or peptide of interest.
13. An expression vector that encodes YebF, or a biologically active variant or portion thereof operatively linked to control nucleotide sequences that direct the transcription and the synthesis of the YebF or a biologically active variant or portion thereof.
14. The expression vector of claim 13 that encodes a fusion protein comprising YebF, or a biologically active variant or portion thereof and a protein, polypeptide or peptide of interest.
15. The expression vector of claim 13 or 14, wherein the nucleotide sequence that encodes the protein, polypeptide or peptide of interest is located downstream of the nucleotide sequence that encodes YebF, or a biologically active variant or portion thereof.
16. The expression vector of claim 13, 14 or 15, for use in *Escherichia coli*.


17. The expression vector of claim 13, 14, 15 or 16 that encodes a fusion protein that further comprises at least one tag.
18. The expression vector of claim 13, 14, 15, 16 or 17 that encodes a fusion protein further comprising at least one protein cleavage site.
19. A recombinant DNA construct comprising in frame for expression, a first nucleotide sequence that encodes YebF, or a biologically active variant or portion thereof, and a second nucleotide sequence that encodes a protein, polypeptide or peptide of interest.
20. The recombinant DNA construct of claim 19 further comprising at least one additional nucleotide sequence located in frame between the first nucleotide sequence and the second nucleotide sequence, or in frame after the second nucleotide sequence, wherein said nucleotide sequence encodes an amino acid sequence selected from the group consisting of: a tag, a protein cleavage site, or a spacer.
21. An expression vector comprising the recombinant DNA construct of claim 19 or 20.
22. The expression vector of claim 21 for use in *Escherichia coli*.
23. A host cell comprising the recombinant DNA construct of claim 19 or 20.
24. The host cell of claim 23, wherein the host cell is *Escherichia coli*.
25. A host cell comprising the expression vector of claim 21 or 22.
26. The host cell of claim 23, wherein the host cell is *Escherichia coli*.
27. A fusion protein encoded by the recombinant DNA construct of claim 19 or 20.
28. A fusion protein encoded by the expression vector of claim 21 or 22.
29. A method of making a fusion protein comprising introducing the expression vector of claim 21 or 22 into a host cell, wherein the host cell containing the expression vector expresses the fusion protein when grown under suitable conditions.

30. An expression vector that encodes the leader sequence of YebF operatively linked to control nucleotide sequences that direct the transcription and the synthesis of the said leader sequence.
31. The expression vector of claim 30 that encodes a protein comprising the leader sequence of YebF and a protein, polypeptide or peptide of interest.
32. The expression vector of claim 30 or 31, wherein the nucleotide sequence that encodes the protein, polypeptide or peptide of interest is located downstream of the nucleotide sequence that encodes the leader sequence of YebF.
33. The expression vector of claim 30, 31 or 32 for use in *Escherichia coli*.
34. The expression vector of claim 30, 31, 32 or 33 that encodes a protein that further comprises at least one tag.
35. The expression vector of claim 30, 31, 32, 33 or 34 that encodes a protein further comprising at least one protein cleavage site.
36. The use of the leader sequence of YebF leader to direct transport of a protein, peptide or polypeptide of interest to the periplasm.
37. The use of claim 36, wherein the leader sequence of YebF is part of a protein that further comprises the protein, polypeptide or peptide of interest.
38. The use of claim 36 or 37 wherein the leader sequence of YebF is fused amino-terminally to the protein, polypeptide or peptide of interest.
39. A method for expressing a protein, polypeptide or peptide of interest in the periplasm, which method comprises:
  - (a) providing an expression vector that encodes a protein comprising the protein, polypeptide or peptide of interest located carboxy-terminally to the leader sequence of YebF, and
  - (b) expressing the protein in a suitable bacterial cell.

Fig 1

	Sec-leader peptide	
<i>Escherichia coli</i>	MKKRGAFLLGLLVSACASVFA-----	ANNE
<i>Shigella flexneri</i>	MKKRGAFLLGRLLVSACASVFA-----	ANNE
<i>Salmonella typhi</i>	MNKRGAALLSLLLSASVSAFA-----	ASTE
<i>Salmonella typhimurium</i>	MNKRGAALLSLLFLSASVSAFA-----	ASTE
<i>Yersinia pestis</i>	MKKTGLALVLATILLGMMGSVHA----	QEPR
<i>Pseudomonas luminescens</i>	MKTCHIINRVGLSGVALLLTVSFTVSA	VSEN

Fig 2



Panel A

Panel B

Fig 3




Fig 4








Fig 5




Panel A




Panel B


Fig 6



Panel A



Panel B

**Fig 7****Panel A**

Antibiotics (μg/ml)	No Plasmid	pMS119EH	pYebFH6/MS	pBR322-Tet	pYebFH6/MS-Tet
Erythromycin	256	64	16	8-16	8-16
Rifampicin	32	32	16		
Vancomycin	256	256	256		
Bacitracin	>1024	1024	>1024		
Azithromycin	All three are same in disc diffusion assays (zone of clearing ~ 6-7 mm).				

**Panel B**

Fig 8






Fig 9



Panel A



Panel B

Fig 10




Fig. 11a


TGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAAC  
AATTTACACAGGAAACAGAATTAGGAGATAGAATTCATGAAAAAAGAGG  
GGCGTTTTTAGGGCTGTTGTTGGTTTCTGCCTGCGCATCAGTTTTCGCTGCCAA  
TAATGAAACCAGCAAGTCGGTCACTTTCCCAAAGTGTGAAGATCTGGATGCTG  
CCGGAATTGCCGCGAGCGTAAAACGTGATTATCAACAAAATCGCGTGGCGCG  
TTGGGCAGATGATCAAAAAATTGTCGGTCAGGCCGATCCCGTGGCTTGGGTCA  
GTTTGCAGGACATTGAGGGTAAAGATGATAAATGGTCAGTACCGCTAACCGTG  
CGTGGTAAAAGTGCCGATATTCATTACCAGGTCAGCGTGGACTGCAAAGCGG  
GAATGGCGGAATATCAGCGGCGTCTCGAGCACCACCACCACCACCTGAGA  
TCTCCGATCCTCTAGAGTCGATCGACCTGCAGCCAAGCTTCTGTTTTGGCGGAT  
GAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGCGGTCT  
GATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCA  
TGCCGAACCTCAGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCC  
CATGCGAGAGTAGGGAACCTGCCAGGCATCAAATAAAACGAAAGGCTCAGTCG  
AAAGACTGGGCCTTTTCGTTTTATCTGTTGTTTGTTCGGTGAACGCTCTCCTGAGT  
AGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGAG  
GGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAA  
GGCCATCCTGACGGATGGCCTTTTTCGTTTCTACAAACTCTTTTGTATTATTTT  
CTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGC  
TTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCC  
CTTATTCCCTTTTTTTCGGCATTTTGCCTTCCTGTTTTTGTCTACCCAGAAACGC  
TGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTACAT  
CGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTTCGCCCCGAAGAAC  
GTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCC  
GTGTTGACGCCGGGCAAGAGCAACTCGGTGCGCCGATACACTATTCTCAGAAT  
GACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGAC  
AGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCC  
AACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCA  
CAACATGGGGGATCATGTAACCTCGCCTTGATCGTTGGGAACCGGAGCTGAATG  
AAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAAC  
AACGTTGCGCAAACCTATTAACCTGGCGAACTACTTACTCTAGCTTCCCGGCAAC  
AATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCG  
GCCCTTCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGG  
GTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCG  
TAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACA  
GATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACCTGTCAGACCAAG  
TTTACTCATATATACTTTAGATTGATTTAAACTTCATTTTTAATTTAAAGGA  
TCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGT  
TTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAAGATCAAAGGATCTTCTTGA  
GATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAACCACCGCTA  
CCAGCGGTGGTTTGTGTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGT  
AACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGT  
AGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTG  
CTAATCCTGTTACCAAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGG  
GTTGGACTCAAGACGATAGTTACCGG

Fig. 11b

ATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTT  
GGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAA  
AGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCA  
GGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGAAACGCCTGGTA  
TCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTG  
ATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTT  
TTACGGTTTCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTAT  
CCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTC  
GCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAG  
AGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTACACCGCA  
CGAACGCCAGCAAGACGTAGCCCAGCGCGTCGGCCAGCTTGCAATTCGCGCT  
AACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCAGTCGGGAAACCTGT  
CGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCG  
TATTGGGCGCCAGGGTGGTTTTTCTTTTACCAGTGAGACGGGCAACAGCTGA  
TTGCCCTTACCGCCTGGCCCTGAGAGAGTTGCAGCAAGCGGTCCACGTGGTT  
TGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGGCGGGATATAACA  
TGAGCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGC  
GCAGCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTG  
GCAACCAGCATCGCAGTGGGAACGATGCCCTCATTACAGCATTTGCATGGTTTG  
TTGAAAACCGGACATGGCACTCCAGTCGCCTTCCCGTTCCGCTATCGGCTGAA  
TTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCGCCGAG  
ACAGAACTTAATGGGCCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGAC  
CAGATGCTCCACGCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGT  
TGATGGGTGTCTGGTCAGAGACATCAAGAAATAACGCCGGAACATTAGTGCA  
GGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGATAGTTAATGATCA  
GCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCG  
ACGCCGCTTCGTTCTACCATCGACACCACCGCTGGCACCCAGTTGATCGGC  
GCGAGATTTAATCGCCGCGACAATTTGCGACGGCGCGTGCAGGGCCAGACTG  
GAGGTGGCAACGCCAATCAGCAACGACTGTTTGCCCGCCAGTTGTTGTGCCAC  
GCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCAATTTTCCCGCGT  
TTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAG  
AGACACCGGCATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACC  
ACCCTGAATTGACTCTCTTCCGGGCGCTATCATGCCATACCGCGAAAGGTTTT  
GCACCATTCGATGGTGTCAACGTAAATGCCGCTTCGCCTTCGCGCGCGAATTG  
CAAGCTGATCCGGAGCTTATCGACTGCACGGTGCACCAATGCTTCTGGCGTCA  
GGCAGCCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAA  
TTCGTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTTGCGCCGACAT  
CATAACGGTTCTGGCAAATATTCTGAAATGAGC



Fig. 12



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/001249

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C12N 15/70, C12P 21/00, C07K 19/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(7): C12N 15/70, C12P 21/00, C07K 19/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Canadian Patent Database; Espacenet; Delphion; PubMed; STN; GenomeQuest.

Terms: gram-negative (bacteria), secre\*, vector/plasmid, and YebF.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6733997 B1 (NATIONAL UNIVERSITY OF SINGAPORE, SINGAPORE [SG]) 11 May 2004 Figures 13-18 and Example 6 in columns 17 and 18	1-29
X	POQUET, I. et al: Stable periplasmic secretion intermediate in the general secretory pathway of <i>Escherichia coli</i> . The EMBO J. January 1993, Vol. 12, no. 1, pp. 271-278. ISSN: 0261-4189	1-3, 5-7, 9-16, 18-29
Y	Whole document	4, 8, 17

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents :	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

7 November 2005 (07-11-2005)

Date of mailing of the international search report

1 December 2005 (01-12-2005)

Name and mailing address of the ISA/CA  
Canadian Intellectual Property Office  
Place du Portage I, C114 - 1st Floor, Box PCT  
50 Victoria Street  
Gatineau, Quebec K1A 0C9  
Facsimile No.: 001(819)953-2476

Authorized officer

X Ma (819) 997-4527

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2005/001249

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BRAUN, P. et al: Proteome-scale purification of human proteins from bacteria. Proc Natl Acad Sci USA. 5 March 2002, Vol. 99, no. 5, pp. 2654-2659, ISSN: 0027-8424 Whole document	4, 8, 17
A	SHOKRI, A. et al: Cell and process design for targeting of recombinant protein into the culture medium of <i>Escherichia coli</i> . Appl Microbiol Biotechnol 2003, Vol. 60, pp. 654-664, ISSN: 0175-7598 Whole document, cited in the application	1-39
A	BROKX, SJ. et al: Genome-wide analysis of lipoprotein expression in <i>Escherichia coli</i> MG1655. J Bacteriol May 2004, Vol. 186, no. 10, pp. 3254-3258, ISSN: 0021-9193 Whole document, cited in the application	1-39

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.  
PCT/CA2005/001249

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US6733997B1	11-05-2004	AU1089200 A WO0026366 A1	22-05-2000 11-05-2000